1. Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 2014;99:3561-9.
[CROSSREF] [PUBMED] [PMC]
2. Doppman JL, Miller DL. Localization of parathyroid tumors in patients with asymptomatic hyperparathyroidism and no previous surgery. J Bone Miner Res 1991;6 Suppl 2:S153-9.
[CROSSREF] [PUBMED]
3. Udelsman R, Lin Z, Donovan P. The superiority of minimally invasive parathyroidectomy based on 1650 consecutive patients with primary hyperparathyroidism. Ann Surg 2011;253:585-91.
[CROSSREF] [PUBMED]
4. Venkat R, Kouniavsky G, Tufano RP, Schneider EB, Dackiw AP, Zeiger MA. Long-term outcome in patients with primary hyperparathyroidism who underwent minimally invasive parathyroidectomy. World J Surg 2012;36:55-60.
[CROSSREF] [PUBMED] [PDF]
5. Kunstman JW, Udelsman R. Superiority of minimally invasive parathyroidectomy. Adv Surg 2012;46:171-89.
[CROSSREF] [PUBMED]
6. Greene AB, Butler RS, McIntyre S, Barbosa GF, Mitchell J, Berber E, et al. National trends in parathyroid surgery from 1998 to 2008: a decade of change. J Am Coll Surg 2009;209:332-43.
[CROSSREF] [PUBMED]
7. Johnson NA, Carty SE, Tublin ME. Parathyroid imaging. Radiol Clin North Am 2011;49:489-509.
[CROSSREF] [PUBMED]
8. Wilhelm SM, Wang TS, Ruan DT, Lee JA, Asa SL, Duh QY, et al. The American Association of Endocrine Surgeons guidelines for definitive management of primary hyperparathyroidism. JAMA Surg 2016;151:959-68.
[CROSSREF] [PUBMED]
9. Silva BC, Cusano NE, Bilezikian JP. Primary hyperparathyroidism. Best Pract Res Clin Endocrinol Metab 2018;32:593-607.
[CROSSREF] [PUBMED]
10. Khan AA, Hanley DA, Rizzoli R, Bollerslev J, Young JE, Rejnmark L, et al. Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management: a Canadian and international consensus. Osteoporos Int 2017;28:1-19.
[CROSSREF] [PUBMED] [PMC] [PDF]
11. Siraj QH. Radionuclide parathyroid imaging. Cham: Springer; 2020 Chapter 4, Diagnostic imaging: structural modalities. 31-40.
12. Leupe PK, Delaere PR, Vander Poorten VL, Debruyne F. Pre-operative imaging in primary hyperparathyroidism with ultrasonography and sestamibi scintigraphy. B-ENT 2011;7:173-80.
[PUBMED]
13. Gooding GA. Sonography of the thyroid and parathyroid. Radiol Clin North Am 1993;31:967-89.
[CROSSREF] [PUBMED]
14. Cheung K, Wang TS, Farrokhyar F, Roman SA, Sosa JA. A meta-analysis of preoperative localization techniques for patients with primary hyperparathyroidism. Ann Surg Oncol 2012;19:577-83.
[CROSSREF] [PUBMED] [PDF]
15. Cunha-Bezerra P, Vieira R, Amaral F, Cartaxo H, Lima T, Montarroyos U, et al. Better performance of four-dimension computed tomography as a localization procedure in normocalcemic primary hyperparathyroidism. J Med Imaging Radiat Oncol 2018;62:493-8.
[CROSSREF] [PDF]
16. Bancos I, Grant CS, Nadeem S, Stan MN, Reading CC, Sebo TJ, et al. Risks and benefits of parathyroid fine-needle aspiration with parathyroid hormone washout. Endocr Pract 2012;18:441-9.
[CROSSREF] [PUBMED]
17. MacFarlane MP, Fraker DL, Shawker TH, Norton JA, Doppman JL, Chang RA, et al. Use of preoperative fine-needle aspiration in patients undergoing reoperation for primary hyperparathyroidism. Surgery 1994;116:959-65.
[PUBMED]
18. Stephen AE, Milas M, Garner CN, Wagner KE, Siperstein AE. Use of surgeon-performed office ultrasound and parathyroid fine needle aspiration for complex parathyroid localization. Surgery 2005;138:1143-51.
[CROSSREF] [PUBMED]
19. Alwaheeb S, Rambaldini G, Boerner S, Coire C, Fiser J, Asa SL. Worrisome histologic alterations following fine-needle aspiration of the parathyroid. J Clin Pathol 2006;59:1094-6.
[CROSSREF] [PUBMED] [PMC]
20. Sisson J, Beierwaltes W. Radiocyanocobalamine (Co-57-B-12) concentration in the parathyroid glands. J Nucl Med 1962;3:160-6.
21. Potchen EJ, Adelstein SJ, Dealy JB Jr. Radioisotope localization of the overactive human parathyroid. Am J Roentgenol Radium Ther Nucl Med 1965;93:955-61.
[PUBMED]
22. Kunstman JW, Kirsch JD, Mahajan A, Udelsman R. Clinical review: parathyroid localization and implications for clinical management. J Clin Endocrinol Metab 2013;98:902-12.
[PUBMED]
23. Fukunaga M, Fujita T, Yonekura Y, Dokoh S, Yamamoto I, Morita R, et al. Visualization of parathyroid tumor with 201Tl-chloride (author’s transl). Kaku Igaku 1979;16:327-31.
[PUBMED]
24. Coakley AJ, Kettle AG, Wells CP, O’Doherty MJ, Collins RE. 99Tcm sestamibi: a new agent for parathyroid imaging. Nucl Med Commun 1989;10:791-4.
[CROSSREF] [PUBMED]
25. Siraj QH. Radionuclide parathyroid imaging. Cham: Springer; 2020. Chapter 5, Parathyroid Scintigraphy. p. 41-60.
[CROSSREF] [PDF]
26. Siraj QH. Radionuclide parathyroid imaging. Cham: Springer; 2020. Chapter 6, Parathyroid PET. p. 61-5.
27. Kettle AG, O’Doherty MJ. Parathyroid imaging: how good is it and how should it be done? Semin Nucl Med 2006;36:206-11.
[CROSSREF] [PUBMED]
28. Hendrikse NH, Franssen EJ, van der Graaf WT, Meijer C, Piers DA, Vaalburg W, et al. 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. Br J Cancer 1998;77:353-8.
[CROSSREF] [PUBMED] [PMC] [PDF]
29. Gupta Y, Ahmed R, Happerfield L, Pinder SE, Balan KK, Wishart GC. P-glycoprotein expression is associated with sestamibi washout in primary hyperparathyroidism. Br J Surg 2007;94:1491-5.
[CROSSREF] [PUBMED] [PDF]
30. Mitchell BK, Cornelius EA, Zoghbi S, Murren JR, Ghoussoub R, Flynn SD, et al. Mechanism of technetium 99m sestamibi parathyroid imaging and the possible role of p-glycoprotein. Surgery 1996;120:1039-45.
[CROSSREF] [PUBMED]
31. Erbil Y, Barbaros U, Yanik BT, Salmaslioglu A, Tunaci M, Adalet I, et al. Impact of gland morphology and concomitant thyroid nodules on preoperative localization of parathyroid adenomas. Laryngoscope 2006;116:580-5.
[CROSSREF] [PUBMED]
32. Vattimo A, Bertelli P, Cintorino M, Burroni L, Volterrani D, Vella A, et al. Hurthle cell tumor dwelling in hot thyroid nodules: preoperative detection with technetium-99m-MIBI dual-phase scintigraphy. J Nucl Med 1998;39:822-5.
[PUBMED]
33. Erbil Y, Barbaros U, Tukenmez M, Issever H, Salmaslioglu A, Adalet I, et al. Impact of adenoma weight and ectopic location of parathyroid adenoma on localization study results. World J Surg 2008;32:566-71.
[CROSSREF] [PUBMED] [PDF]
34. Lavely WC, Goetze S, Friedman KP, Leal JP, Zhang Z, Garret-Mayer E, et al. Comparison of SPECT/CT, SPECT, and planar imaging with single- and dual-phase (99m)Tc-sestamibi parathyroid scintigraphy. J Nucl Med 2007;48:1084-9.
[CROSSREF] [PUBMED]
35. Chien D, Jacene H. Imaging of parathyroid glands. Otolaryngol Clin North Am 2010;43:399-415.
[CROSSREF] [PUBMED]
36. Ruda JM, Hollenbeak CS, Stack BC Jr. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg 2005;132:359-72.
[CROSSREF] [PUBMED] [PDF]
37. Krausz Y, Bettman L, Guralnik L, Yosilevsky G, Keidar Z, Bar-Shalom R, et al. Technetium-99m-MIBI SPECT/CT in primary hyperparathyroidism. World J Surg 2006;30:76-83.
[CROSSREF] [PUBMED] [PDF]
38. Neumann DR, Obuchowski NA, Difilippo FP. Preoperative 123I/99mTc-sestamibi subtraction SPECT and SPECT/CT in primary hyperparathyroidism. J Nucl Med 2008;49:2012-7.
[CROSSREF] [PUBMED]
39. Kim YI, Jung YH, Hwang KT, Lee HY. Efficacy of 99mTc-sestamibi SPECT/CT for minimally invasive parathyroidectomy: comparative study with 99mTc-sestamibi scintigraphy, SPECT, US and CT. Ann Nucl Med 2012;26:804-10.
[CROSSREF] [PUBMED] [PDF]
40. Akram K, Parker JA, Donohoe K, Kolodny G. Role of single photon emission computed tomography/computed tomography in localization of ectopic parathyroid adenoma: a pictorial case series and review of the current literature. Clin Nucl Med 2009;34:500-2.
[PUBMED]
41. Wong KK, Fig LM, Gross MD, Dwamena BA. Parathyroid adenoma localization with 99mTc-sestamibi SPECT/CT: a meta-analysis. Nucl Med Commun 2015;36:363-75.
[PUBMED]
42. Beheshti M, Hehenwarter L, Paymani Z, Rendl G, Imamovic L, Rettenbacher R, et al. 18F-fluorocholine PET/CT in the assessment of primary hyperparathyroidism compared with 99mTc-MIBI or 99mTc-tetrofosmin SPECT/CT: a prospective dual-centre study in 100 patients. Eur J Nucl Med Mol Imaging 2018;45:1762-71.
[CROSSREF] [PUBMED] [PMC] [PDF]
43. Cuderman A, Senica K, Rep S, Hocevar M, Kocjan T, Sever MJ, et al. 18F-fluorocholine PET/CT in primary hyperparathyroidism: superior diagnostic performance to conventional scintigraphic imaging for localization of hyperfunctioning parathyroid glands. J Nucl Med 2020;61:577-83.
[CROSSREF] [PUBMED]
44. Tay D, Das JP, Yeh R. Preoperative localization for primary hyperparathyroidism: a clinical review. Biomedicines 2021;9:390.
[CROSSREF] [PUBMED] [PMC]
45. Gomez-Ramirez J, Gomez-Valdazo A, Luengo P, Porrero B, Osorio I, Rivas S. Comparative prospective study on the presentation of normocalcemic primary hyperparathyroidism: is it more aggressive than the hypercalcemic form? Am J Surg 2020;219:150-3.
[CROSSREF] [PUBMED]
46. Boccalatte LA, Higuera F, Gomez NL, de la Torre AY, Mazzaro EL, Galich AM, et al. Usefulness of 18F-fluorocholine positron emission tomography-computed tomography in locating lesions in hyperparathyroidism: a systematic review. JAMA Otolaryngol Head Neck Surg 2019;145:743-50.
[CROSSREF] [PUBMED]
47. Saerens J, Velkeniers B, Keyaerts M, Raeymaeckers S, Vanhoeij M, Blotwijk S, et al. Value of [11C]-methionine PET/CT in preoperative localization of parathyroid adenomas. Horm Metab Res 2021;53:444-52.
[CROSSREF] [PUBMED]
48. Yuan L, Liu J, Kan Y, Yang J, Wang X. The diagnostic value of 11C-methionine PET in hyperparathyroidism with negative 99mTc-MIBI SPECT: a meta-analysis. Acta Radiol 2017;58:558-64.
[CROSSREF] [PUBMED] [PDF]
49. Hellman P, Ahlstrom H, Bergstrom M, Sundin A, Langstrom B, Westerberg G, et al. Positron emission tomography with 11C-methionine in hyperparathyroidism. Surgery 1994;116:974-81.
[PUBMED]
50. Hayakawa N, Nakamoto Y, Kurihara K, Yasoda A, Kanamoto N, Miura M, et al. A comparison between 11C-methionine PET/CT and MIBI SPECT/CT for localization of parathyroid adenomas/hyperplasia. Nucl Med Commun 2015;36:53-9.
[CROSSREF] [PUBMED]
51. Weber T, Cammerer G, Schick C, Solbach C, Hillenbrand A, Barth TF, et al. C-11 methionine positron emission tomography/computed tomography localizes parathyroid adenomas in primary hyperparathyroidism. Horm Metab Res 2010;42:209-14.
[CROSSREF] [PUBMED]
52. Tang BN, Moreno-Reyes R, Blocklet D, Corvilain B, Cappello M, Delpierre I, et al. Accurate pre-operative localization of pathological parathyroid glands using 11C-methionine PET/CT. Contrast Media Mol Imaging 2008;3:157-63.
[CROSSREF] [PUBMED]
53. Rubello D, Fanti S, Nanni C, Farsad M, Castellucci P, Boschi S, et al. 11C-methionine PET/CT in 99mTc-sestamibi-negative hyperparathyroidism in patients with renal failure on chronic haemodialysis. Eur J Nucl Med Mol Imaging 2006;33:453-9.
[CROSSREF] [PUBMED] [PDF]
54. Caldarella C, Treglia G, Isgro MA, Giordano A. Diagnostic performance of positron emission tomography using 11C-methionine in patients with suspected parathyroid adenoma: a meta-analysis. Endocrine 2013;43:78-83.
[CROSSREF] [PUBMED] [PDF]
55. Treglia G, Giovannini E, Di Franco D, Calcagni ML, Rufini V, Picchio M, et al. The role of positron emission tomography using carbon-11 and fluorine-18 choline in tumors other than prostate cancer: a systematic review. Ann Nucl Med 2012;26:451-61.
[CROSSREF] [PUBMED] [PDF]
56. Kluijfhout WP, Pasternak JD, Drake FT, Beninato T, Gosnell JE, Shen WT, et al. Use of PET tracers for parathyroid localization: a systematic review and meta-analysis. Langenbecks Arch Surg 2016;401:925-35.
[CROSSREF] [PUBMED] [PMC] [PDF]
57. Mathey C, Keyzer C, Blocklet D, Van Simaeys G, Trotta N, Lacroix S, et al. 18F-fluorocholine PET/CT is more sensitive than 11C-methionine PET/CT for the localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism. J Nucl Med 2022;63:785-91.
[CROSSREF] [PUBMED]
58. Araz M, Soydal C, Ozkan E, Kir MK, Ibis E, Gullu S, et al. The efficacy of fluorine-18-choline PET/CT in comparison with 99mTc-MIBI SPECT/CT in the localization of a hyperfunctioning parathyroid gland in primary hyperparathyroidism. Nucl Med Commun 2018;39:989-94.
[CROSSREF] [PUBMED]
59. Ferrari C, Santo G, Mammucci P, Pisani AR, Sardaro A, Rubini G. Diagnostic value of choline PET in the preoperative localization of hyperfunctioning parathyroid gland(s): a comprehensive overview. Biomedicines 2021;9:231.
[CROSSREF] [PUBMED] [PMC]
60. Broos WA, Wondergem M, Knol RJ, van der Zant FM. Parathyroid imaging with 18F-fluorocholine PET/CT as a first-line imaging modality in primary hyperparathyroidism: a retrospective cohort study. EJNMMI Res 2019;9:72.
[CROSSREF] [PUBMED] [PMC] [PDF]
61. Treglia G, Piccardo A, Imperiale A, Strobel K, Kaufmann PA, Prior JO, et al. Diagnostic performance of choline PET for detection of hyperfunctioning parathyroid glands in hyperparathyroidism: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2019;46:751-65.
[CROSSREF] [PUBMED] [PDF]
62. Rep S, Hocevar M, Vaupotic J, Zdesar U, Zaletel K, Lezaic L. 18F-choline PET/CT for parathyroid scintigraphy: significantly lower radiation exposure of patients in comparison to conventional nuclear medicine imaging approaches. J Radiol Prot 2018;38:343-56.
[CROSSREF] [PUBMED] [PDF]
63. Kawada K, Iwamoto M, Sakai Y. Mechanisms underlying 18F-fluorodeoxyglucose accumulation in colorectal cancer. World J Radiol 2016;8:880-6.
[CROSSREF] [PUBMED] [PMC]
64. Evangelista L, Sorgato N, Torresan F, Boschin IM, Pennelli G, Saladini G, et al. FDG-PET/CT and parathyroid carcinoma: review of literature and illustrative case series. World J Clin Oncol 2011;2:348-54.
[CROSSREF] [PUBMED] [PMC]
65. Neumann DR, Esselstyn CB, Kim EY. Recurrent postoperative parathyroid carcinoma: FDG-PET and sestamibi-SPECT findings. J Nucl Med 1996;37:2000-1.
[PUBMED]
66. Neumann DR, Esselstyn CB, Maclntyre WJ, Go RT, Obuchowski NA, Chen EQ, et al. Comparison of FDG-PET and sestamibi-SPECT in primary hyperparathyroidism. J Nucl Med 1996;37:1809-15.
[PUBMED]
67. Neumann DR, Esselstyn CB Jr, MacIntyre WJ, Chen EQ, Go RT, Kohse LM, et al. Primary hyperparathyroidism: preoperative parathyroid imaging with regional body FDG PET. Radiology 1994;192:509-12.
[CROSSREF] [PUBMED]
68. Melon P, Luxen A, Hamoir E, Meurisse M. Fluorine-18-fluorodeoxyglucose positron emission tomography for preoperative parathyroid imaging in primary hyperparathyroidism. Eur J Nucl Med 1995;22:556-8.
[CROSSREF] [PUBMED] [PDF]
69. Strauss LG. Positron emission tomography: current role for diagnosis and therapy monitoring in oncology. Oncologist 1997;2:381-8.
[CROSSREF] [PUBMED] [PDF]
70. Strauss LG. Sensitivity and specificity of positron emission tomography (PET) for the diagnosis of lymph node metastases. Recent Results Cancer Res 2000;157:12-9.
[CROSSREF] [PUBMED]
71. Morgat C, Velayoudom-Cephise FL, Schwartz P, Guyot M, Gaye D, Vimont D, et al. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1. Eur J Nucl Med Mol Imaging 2016;43:1258-66.
[CROSSREF] [PUBMED] [PDF]
72. Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schafer M, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007;34:1617-26.
[CROSSREF] [PUBMED] [PDF]
73. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48:508-18.
[CROSSREF] [PUBMED]
74. Schreiter NF, Bartels AM, Froeling V, Steffen I, Pape UF, Beck A, et al. Searching for primaries in patients with neuroendocrine tumors (NET) of unknown primary and clinically suspected NET: evaluation of Ga-68 DOTATOC PET/CT and In-111 DTPA octreotide SPECT/CT. Radiol Oncol 2014;48:339-47.
[CROSSREF] [PUBMED] [PMC]
75. Sharma P, Mukherjee A, Karunanithi S, Naswa N, Kumar R, Ammini AC, et al. Accuracy of 68Ga DOTANOC PET/CT imaging in patients with multiple endocrine neoplasia syndromes. Clin Nucl Med 2015;40:e351-6.
[CROSSREF] [PUBMED]
76. Froeling V, Elgeti F, Maurer MH, Scheurig-Muenkler C, Beck A, Kroencke TJ, et al. Impact of Ga-68 DOTATOC PET/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia. Ann Nucl Med 2012;26:738-43.
[CROSSREF] [PUBMED] [PDF]
77. Rodgers SE, Hunter GJ, Hamberg LM, Schellingerhout D, Doherty DB, Ayers GD, et al. Improved preoperative planning for directed parathyroidectomy with 4-dimensional computed tomography. Surgery 2006;140:932-41.
[CROSSREF] [PUBMED]
78. Starker LF, Mahajan A, Bjorklund P, Sze G, Udelsman R, Carling T. 4D parathyroid CT as the initial localization study for patients with de novo primary hyperparathyroidism. Ann Surg Oncol 2011;18:1723-8.
[CROSSREF] [PUBMED] [PDF]
79. Mortenson MM, Evans DB, Lee JE, Hunter GJ, Shellingerhout D, Vu T, et al. Parathyroid exploration in the reoperative neck: improved preoperative localization with 4D-computed tomography. J Am Coll Surg 2008;206:888-96.
[CROSSREF] [PUBMED]
80. Lubitz CC, Hunter GJ, Hamberg LM, Parangi S, Ruan D, Gawande A, et al. Accuracy of 4-dimensional computed to mography in poorly localized patients with primary hyperparathyroidism. Surgery 2010;148:1129-38.
[CROSSREF] [PUBMED]
81. Eichhorn-Wharry LI, Carlin AM, Talpos GB. Mild hypercalcemia: an indication to select 4-dimensional computed tomography scan for preoperative localization of parathyroid adenomas. Am J Surg 2011;201:334-8.
[CROSSREF] [PUBMED]
82. Welling RD, Olson JA Jr, Kranz PG, Eastwood JD, Hoang JK. Bilateral retropharyngeal parathyroid hyperplasia detected with 4D multidetector row CT. AJNR Am J Neuroradiol 2011;32:E80-2.
[CROSSREF] [PUBMED] [PMC]
83. Russell MT, Fink JR, Rebeles F, Kanal K, Ramos M, Anzai Y. Balancing radiation dose and image quality: clinical applications of neck volume CT. AJNR Am J Neuroradiol 2008;29:727-31.
[CROSSREF] [PUBMED] [PMC]
84. Ibraheem K, Toraih EA, Haddad AB, Farag M, Randolph GW, Kandil E. Selective parathyroid venous sampling in primary hyperparathyroidism: a systematic review and meta-analysis. Laryngoscope 2018;128:2662-7.
[CROSSREF] [PUBMED] [PDF]
85. Taslakian B, Trerotola SO, Sacks B, Oklu R, Deipolyi A. The essentials of parathyroid hormone venous sampling. Cardiovasc Intervent Radiol 2017;40:9-21.
[CROSSREF] [PUBMED] [PDF]
86. Ogilvie CM, Brown PL, Matson M, Dacie J, Reznek RH, Britton K, et al. Selective parathyroid venous sampling in patients with complicated hyperparathyroidism. Eur J Endocrinol 2006;155:813-21.
[CROSSREF] [PUBMED]
87. Lee J, Hong N, Kim BM, Kim DJ, Yun M, Jeong JJ, et al. Evaluation of an optimal cutoff of parathyroid venous sampling gradient for localizing primary hyperparathyroidism. J Bone Miner Metab 2020;38:570-80.
[CROSSREF] [PUBMED] [PDF]
88. Seehofer D, Steinmuller T, Rayes N, Podrabsky P, Riethmuller J, Klupp J, et al. Parathyroid hormone venous sampling before reoperative surgery in renal hyperparathyroidism: comparison with noninvasive localization procedures and review of the literature. Arch Surg 2004;139:1331-8.
[CROSSREF] [PUBMED]
89. Jones JJ, Brunaud L, Dowd CF, Duh QY, Morita E, Clark OH. Accuracy of selective venous sampling for intact parathyroid hormone in difficult patients with recurrent or persistent hyperparathyroidism. Surgery 2002;132:944-51.
[CROSSREF] [PUBMED]
90. Jaskowiak N, Norton JA, Alexander HR, Doppman JL, Shawker T, Skarulis M, et al. A prospective trial evaluating a standard approach to reoperation for missed parathyroid adenoma. Ann Surg 1996;224:308-21.
[CROSSREF] [PUBMED] [PMC]
91. Witteveen JE, Kievit J, van Erkel AR, Morreau H, Romijn JA, Hamdy NA. The role of selective venous sampling in the management of persistent hyperparathyroidism revisited. Eur J Endocrinol 2010;163:945-52.
[CROSSREF] [PUBMED]
92. Ho J, Kim D, Lee JE, Hong N, Kim BM, Kim DJ, et al. Parathyroid venous sampling for the preoperative localisation of parathyroid adenoma in patients with primary hyperparathyroidism. Sci Rep 2022;12:7058.
[CROSSREF] [PUBMED] [PMC] [PDF]
93. Mahajan A, Starker LF, Ghita M, Udelsman R, Brink JA, Carling T. Parathyroid four-dimensional computed tomography: evaluation of radiation dose exposure during preoperative localization of parathyroid tumors in primary hyperparathyroidism. World J Surg 2012;36:1335-9.
[CROSSREF] [PUBMED] [PDF]
94. Mettler FA Jr, Huda W, Yoshizumi TT, Mahesh M. Effective doses in radiology and diagnostic nuclear medicine: a catalog. Radiology 2008;248:254-63.
[CROSSREF] [PUBMED]
95. Akerstrom G, Malmaeus J, Bergstrom R. Surgical anatomy of human parathyroid glands. Surgery 1984;95:14-21.
[PUBMED]
96. Bilezikian JP, Silverberg SJ, Bandeira F, Cetani F, Chandran M, Cusano NE, et al. Task Force #8: management of primary hyperparathyroidism. J Bone Miner Res 2022 Aug 28 [Epub].
https://doi.org/10.1002/jbmr.4682.
[CROSSREF]
97. Solorzano CC, Thomas G, Baregamian N, Mahadevan-Jansen A. Detecting the near infrared autofluorescence of the human parathyroid: hype or opportunity? Ann Surg 2020;272:973-85.
[PUBMED]
98. Alazraki N, Glass EC, Castronovo F, Olmos RA, Podoloff D; Society of Nuclear Medicine. Procedure guideline for lymphoscintigraphy and the use of intraoperative gamma probe for sentinel lymph node localization in melanoma of intermediate thickness 1.0. J Nucl Med 2002;43:1414-8.
[PUBMED]
99. Buicko JL, Kichler KM, Amundson JR, Scurci S, Kozol RA. The sestamibi paradox: improving intraoperative localization of parathyroid adenomas. Am Surg 2017;83:832-5.
[CROSSREF] [PUBMED] [PDF]
100. Chen H, Sippel RS, Schaefer S. The effectiveness of radioguided parathyroidectomy in patients with negative technetium tc 99m-sestamibi scans. Arch Surg 2009;144:643-8.
[CROSSREF] [PUBMED]
101. Daliakopoulos SI, Chatzoulis G, Lampridis S, Pantelidou V, Zografos O, Ioannidis K, et al. Gamma probe-assisted excision of an ectopic parathyroid adenoma located within the thymus: case report and review of the literature. J Cardiothorac Surg 2014;9:62.
[CROSSREF] [PUBMED] [PMC] [PDF]
102. Jaskowiak NT, Sugg SL, Helke J, Koka MR, Kaplan EL. Pitfalls of intraoperative quick parathyroid hormone monitoring and gamma probe localization in surgery for primary hyperparathyroidism. Arch Surg 2002;137:659-69.
[CROSSREF] [PUBMED]
103. Tobin K, Ayers RR, Rajaei M, Sippel RS, Balentine CJ, Elfenbein D, et al. Use of the gamma probe to identify multigland disease in primary hyperparathyroidism. Int J Endocr Oncol 2016;3:13-9.
[CROSSREF] [PUBMED] [PMC]
104. Ladurner R, Sommerey S, Arabi NA, Hallfeldt KK, Stepp H, Gallwas JK. Intraoperative near-infrared autofluorescence imaging of parathyroid glands. Surg Endosc 2017;31:3140-5.
[CROSSREF] [PUBMED] [PDF]
105. Han N, Bumpous JM, Goldstein RE, Fleming MM, Flynn MB. Intra-operative parathyroid identification using methylene blue in parathyroid surgery. Am Surg 2007;73:820-3.
[CROSSREF] [PUBMED] [PDF]
106. Suzuki T, Numata T, Shibuya M. Intraoperative photodynamic detection of normal parathyroid glands using 5-aminolevulinic acid. Laryngoscope 2011;121:1462-6.
[CROSSREF] [PUBMED] [PDF]
107. Kose E, Kahramangil B, Aydin H, Donmez M, Berber E. Heterogeneous and low-intensity parathyroid autofluorescence: patterns suggesting hyperfunction at parathyroid exploration. Surgery 2019;165:431-7.
[CROSSREF] [PUBMED]
108. Falco J, Dip F, Quadri P, de la Fuente M, Prunello M, Rosenthal RJ. Increased identification of parathyroid glands using near infrared light during thyroid and parathyroid surgery. Surg Endosc 2017;31:3737-42.
[CROSSREF] [PUBMED] [PDF]
109. Ladurner R, Al Arabi N, Guendogar U, Hallfeldt K, Stepp H, Gallwas J. Near-infrared autofluorescence imaging to detect parathyroid glands in thyroid surgery. Ann R Coll Surg Engl 2018;100:33-6.
[CROSSREF] [PUBMED] [PMC]
110. Squires MH, Jarvis R, Shirley LA, Phay JE. Intraoperative parathyroid autofluorescence detection in patients with primary hyperparathyroidism. Ann Surg Oncol 2019;26:1142-8.
[CROSSREF] [PUBMED] [PDF]
111. Merrill AL, Sims SS, Dedhia PH, Rossfeld K, Lott Limbach A, Duh QY, et al. Near-infrared autofluorescence features of parathyroid carcinoma. J Endocr Soc 2022;6:bvac090.
[CROSSREF] [PUBMED] [PMC] [PDF]
112. Morris MA, Saboury B, Ahlman M, Malayeri AA, Jones EC, Chen CC, et al. Parathyroid imaging: past, present, and future. Front Endocrinol (Lausanne) 2022;12:760419.
[CROSSREF] [PUBMED] [PMC]
113. Katz SC, Wang GJ, Kramer EL, Roses DF. Limitations of technetium 99m sestamibi scintigraphic localization for primary hyperparathyroidism associated with multiglandular disease. Am Surg 2003;69:170-5.
[CROSSREF] [PUBMED] [PDF]
114. Parikh AM, Suliburk JW, Moron FE. Imaging localization and surgical approach in the management of ectopic parathyroid adenomas. Endocr Pract 2018;24:589-98.
[CROSSREF] [PUBMED]
115. Udelsman R. Approach to the patient with persistent or recurrent primary hyperparathyroidism. J Clin Endocrinol Metab 2011;96:2950-8.
[CROSSREF] [PUBMED]
116. Bioletto F, Barale M, Parasiliti-Caprino M, Prencipe N, Berton AM, Procopio M, et al. Comparison of the diagnostic accuracy of 18F-fluorocholine PET and 11C-methionine PET for parathyroid localization in primary hyperparathyroidism: a systematic review and meta-analysis. Eur J Endocrinol 2021;185:109-20.
[CROSSREF] [PUBMED]
117. Singer MC, Pucar D, Mathew M, Terris DJ. Improved localization of sestamibi imaging at high-volume centers. Laryngoscope 2013;123:298-301.
[CROSSREF] [PUBMED]